双特异性抗体NXT007在A型血友病猴中发挥止血活性足以维持非血友病状态
研究通过噬菌体库筛选和抗体优化获得靶向FIXa和FX的双特异性抗体NXT007,在体外A型血友病血浆凝血酶生成试验和非人灵长类获得性A型血友病模型中评估其活性。NXT007体外凝血酶生成活性与国际标准FVIII活性(100 IU/dL)相当,远高于艾美赛珠单抗;体内止血活性所需血浆浓度约为艾美赛珠单抗历史数据的1/30。
要点
- NXT007体外凝血酶生成活性与国际标准FVIII活性(100 IU/dL)相当,远高于艾美赛珠单抗。
- NXT007体内止血活性所需血浆浓度约为艾美赛珠单抗历史数据的1/30。
- NXT007体内清除率低于典型单克隆抗体,提示增强FcRn结合的Fc工程有效。
核心结论
- NXT007是一种成功创建的高效双特异性抗体,非临床结果提示其有潜力使A型血友病患者凝血潜力维持在非血友病范围,或实现比艾美赛珠单抗更便利的给药方案。
研究设计与样本
- 从噬菌体库筛选艾美赛珠单抗重链的新轻链配对并进行抗体优化,通过体外A型血友病血浆凝血酶生成试验和获得性A型血友病非人灵长类模型进行体内外评价。
主要发现
- 在组织因子触发下,NXT007体外凝血酶生成活性与国际标准FVIII活性(100 IU/dL)相当,远高于艾美赛珠单抗。
- NXT007在约30倍低于艾美赛珠单抗历史数据的血浆浓度下即表现出强效体内止血活性。
- NXT007与艾美赛珠单抗之间的剂量偏移在体外和体内结果一致。
- NXT007体内清除率低于典型单克隆抗体所显示的水平,提示增强FcRn结合的Fc工程有效。
关键数值与推荐
- NXT007体外凝血酶生成活性与国际标准FVIII活性(100 IU/dL)相当。
- NXT007体内止血活性所需血浆浓度约为艾美赛珠单抗历史数据的1/30。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emicizumab, a factor (F) VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment option for people with hemophilia A (PwHA). However, a small proportion of PwHA still experience bleeds even under emicizumab prophylaxis, as observed in the long-term outcomes of clinical studies. A more potent BsAb may be desirable for such patients. OBJECTIVES: To identify a potent BsAb to FIXa and FX, NXT007, surpassing emicizumab by in vitro and in vivo evaluation. METHODS: New pairs of light chains for emicizumab's heavy chains were screened from phage libraries, and subsequent antibody optimization was performed. For in vitro evaluation, thrombin generation assays were performed with hemophilia A plasma. In vivo hemostatic activity was evaluated in a nonhuman primate model of acquired hemophilia A. RESULTS: NXT007 exhibited an in vitro thrombin generation activity comparable to the international standard activity of FVIII (100 IU/dL), much higher than emicizumab, when triggered by tissue factor. NXT007 also demonstrated a potent in vivo hemostatic activity at approximately 30-fold lower plasma concentrations than emicizumab's historical data. In terms of dose shift between NXT007 and emicizumab, the in vitro and in vivo results were concordant. Regarding pharmacokinetics, NXT007 showed lower in vivo clearance than those shown by typical monoclonal antibodies, suggesting that the Fc engineering to enhance FcRn binding worked well. CONCLUSION: NXT007, a potent BsAb, was successfully created. Nonclinical results suggest that NXT007 would have a potential to keep a nonhemophilic range of coagulation potential in PwHA or to realize more convenient dosing regimens than emicizumab.
引用
- Teranishi-Ikawa Y, Soeda T, Koga H, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. J Thromb Haemost. 2023. PMID: 37940048. doi:10.1016/j.jtha.2023.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。